APO-CANDESARTAN TABLET
Country: Kanada
Bahasa: Inggeris
Sumber: Health Canada
Ciri produk
(SPC)
29-01-2019
Beberapa dokumen untuk produk ini saat ini tidak tersedia, anda dapat mengirim permintaan ke layanan pelanggan kami dan kami akan memberitahu Anda segera setelah kami dapat memperolehnya.
Hantar permintaan.
Hantar permintaan.
Bahan aktif:
CANDESARTAN CILEXETIL
Boleh didapati daripada:
APOTEX INC
Kod ATC:
C09CA06
INN (Nama Antarabangsa):
CANDESARTAN
Dos:
4MG
Borang farmaseutikal:
TABLET
Komposisi:
CANDESARTAN CILEXETIL 4MG
Laluan pentadbiran:
ORAL
Unit dalam pakej:
10/100
Jenis preskripsi:
Prescription
Kawasan terapeutik:
ANGIOTENSIN II RECEPTOR ANTAGONISTS
Ringkasan produk:
Active ingredient group (AIG) number: 0135220001; AHFS:
Status kebenaran:
APPROVED
Tarikh kebenaran:
2011-04-26
Ciri produk
_APO-CANDESARTAN Tablets Product Monograph_
Page 1 of 34
PRODUCT MONOGRAPH
PR
APO-CANDESARTAN
CANDESARTAN CILEXETIL TABLETS USP
4 MG, 8 MG, 16 MG AND 32 MG
ANGIOTENSIN II AT
1 RECEPTOR BLOCKER
APOTEX INC.
DATE OF REVISION:
150 SIGNET DRIVE
JANUARY 29, 2019
TORONTO, ONTARIO
M9L 1T9
CONTROL NUMBER: 222632
_APO-CANDESARTAN Tablets Product Monograph_
Page 2 of 34
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.................................................................. 3
_SUMMARY PRODUCT INFORMATION
.................................................................................................
3_
_INDICATIONS AND CLINICAL USE
.......................................................................................................
3_
_CONTRAINDICATIONS
...........................................................................................................................
3_
_WARNINGS AND
PRECAUTIONS..........................................................................................................
4_
_ADVERSE REACTIONS
..........................................................................................................................
7_
_DRUG INTERACTIONS
.........................................................................................................................
13_
_DOSAGE AND ADMINISTRATION
.......................................................................................................
16_
_OVERDOSAGE
.....................................................................................................................................
18_
_ACTION AND CLINICAL PHARMACOLOGY
........................................................................................
18_
_STORAGE AND STABILITY
..................................................................................................................
21_
_DOSAGE FORMS, COMPOSITION AND PACKAGING
.......................................................................
21_
PART II: SCIENTIFIC INFORMATION
..................
Baca dokumen lengkap
